Taurolidine and oxidative stress: A rationale for local treatment of mesothelioma

European Respiratory Journal

Volumn 34, Issue 6, 2009, Pages 1399-1407

  Aceto, N ^a,f   Bertino, P ^a   Barbone, D ^a,g   Tassi, G ^b   Manzo, L ^c   Porta, C ^d   Mutti, L ^e   Gaudino, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Department of Paediatrics   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Local Health Unit 11   (Italy)

^f Friedrich Mietscher Institute   (Switzerland)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Akt; Apoptosis; Malignant mesothelioma; Oxidative stress; Taurolidine

Indexed keywords

ACETYLCYSTEINE; CASPASE 8; GLUTATHIONE ETHYL ESTER; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRITE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 1ALPHA; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; TAUROLIDINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MESOTHELIOMA; MESOTHELIUM CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; DNA; FIBROBLASTS; HUMANS; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MESOTHELIOMA; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; TAURINE; THIADIAZINES; TIME FACTORS;

EID: 73249125863     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00102308     Document Type: Article

References (35)

1. Pass HI, Vogelzang N, Hahn S, et al. Malignant pleural mesothelioma. Curr Probl Cancer 2004; 28: 93-174.
2. Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007; 7: 147-154.
3. Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006; 103: 14128-14133.
4. Cacciotti P, Barbone D, Porta C, et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005; 65: 5256-5262.
5. Bertino P, Marconi A, Palumbo L, et al. Erionite and asbestos differently cause transformation of human mesothelial cells. Int J Cancer 2007; 121: 12-20.
6. Treutner KH, Bertram P, Lerch MM, et al. Prevention of postoperative adhesions by single intraperitoneal medication. J Surg Res 1995; 59: 764-771.
7. Braumann C, Henke W, Jacobi CA, et al. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer 2004; 112: 225-230.
8. Jacobi CA, Menenakos C, Braumann C. Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 2005; 16: 917-921.
9. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, et al. The effect of taurolidine on brain tumor cells. Anticancer Res 2002; 22: 809-814.
10. McCourt M, Wang JH, Sookhai S, et al. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000; 7: 685-691.
11. Braumann C, Stuhldreier B, Bobrich E, et al. High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats. J Surg Res 2005; 129: 129-135.
12. Altomare DA, You H, Xiao GH, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005; 24: 6080-6089.
13. Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007; 62: 690-695.
14. Bertino P, Piccardi F, Porta C, et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008; 14: 541-548.
15. Gao N, Rahmani M, Dent P, et al. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005; 24: 3797-3809.
16. Rodak R, Kubota H, Ishihara H, et al. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 2005; 102: 1055-1068.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
18. Toyokuni S, Sagripanti JL. Association between 8-hydroxy-29- deoxyguanosine formation and DNA strand breaks mediated by copper and iron. Free Radic Biol Med 1996; 20: 859-864.
19. Stewart JHt, Nguyen DM, Chen GA, et al. Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway. J Thorac Cardiovasc Surg 2002; 123: 295-302.
20. Altomare DA, Vaslet CA, Skele KL, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 2005; 65: 8090-8095.
21. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-4245.
22. Ramaswamy S, Nakamura N, Vazquez F, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999; 96: 2110-2115.
23. Wu LL, Chiou CC, Chang PY, et al. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339: 1-9.
24. Santangelo F. Intracellular thiol concentration modulating inflammatory response: influence on the regulation of cell functions through cysteine prodrug approach. Curr Med Chem 2003; 10: 2599-2610.
25. Ribizzi I, Darnowski JW, Goulette FA, et al. Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging. Bone Marrow Transplant 2002; 29: 313-319.
26. Nici L, Monfils B, Calabresi P. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 2004; 10: 7655-7661.
27. Opitz I, Sigrist B, Hillinger S, et al. Taurolidine and povidoneiodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer 2007; 56: 327-336.
28. Torres M, Forman HJ. Redox signaling and the MAP kinase pathways. Biofactors 2003; 17: 287-296.
29. Stapelberg M, Gellert N, Swettenham E, et al. Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. J Biol Chem 2005; 280: 25369-25376.
30. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005; 24: 7746-7755.
31. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005; 15: 34-41.
32. Ruvolo PP. Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia 2001; 15: 1153-1160.
33. el-Remessy AB, Bartoli M, Platt DH, et al. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 2005; 118: 243-252.
34. Esposito F, Chirico G, Montesano Gesualdi N, et al. Protein kinase B activation by reactive oxygen species is independent of tyrosine kinase receptor phosphorylation and requires SRC activity. J Biol Chem 2003; 278: 20828-20834.
35. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-10837.